Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: Safety and efficacy data in a series of 21 patients from Europe and the USA

Bone Marrow Transplantation

Volumn 47, Issue 1, 2012, Pages 18-23

  Douglas, K W ^a   Parker, A N ^a   Hayden, P J ^b   Rahemtulla, A ^c   D'Addio, A ^d   Lemoli, R M ^d   Rao, K ^e   Maris, M ^f   Pagliuca, A ^g   Uberti, J ^h   Scheid, C ⁱ   Noppeney, R ^j   Cook, G ^k   Bokhari, S W ^l   Worel, N ^m   Mikala, G ⁿ   Masszi, T ⁿ   Taylor, R ^o   Treisman, J ^o  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^f Rocky Mountain Blood Marrow Transplant Program   (United States)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h KARMANOS CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j UNIVERSITY HOSPITAL ESSEN   (Germany)

^k ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^l UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁿ Szent Laszlo Hospital   (Hungary)

^o ST LUKE S MEDICAL CENTER   (United States)

more..

Author keywords

autologous HSC transplant; dialysis; kidney failure; myeloma; plerixafor

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BORTEZOMIB; CD34 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; PLERIXAFOR; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EUROPE; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; MYELOMA; NAUSEA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT FAILURE; UNITED STATES; VOMITING;

ADULT; AGED; ANTI-HIV AGENTS; BLOOD COMPONENT REMOVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RENAL DIALYSIS; RENAL INSUFFICIENCY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855749342     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.9     Document Type: Article

References (17)

1. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. Medical Research Council Adult Leukemia Working Party. High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
2. Lee C-K, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823-828. (Pubitemid 38519243)
3. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27-33. (Pubitemid 40873958)
4. Yamamoto R, Kanda Y, Matsuyama T, Oshima K, Nannya Y, Suguro M et al. Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure. Bone Marrow Transplant 2000; 26: 685-688.
5. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059-2064.
6. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker S-A, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331-338. (Pubitemid 351330727)
7. Duarte RF, Shaw BE, Marín P, Kottaridis P, Ortiz M, Morante C et al. Plerixafor plus G-CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilisation attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46: 52-58.
8. Weaver CH, Tauer K, Zhen B, Schwartzberg LS, Hazelton B, Weaver Z et al. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. J Hematother 1998; 7: 241-249.
9. Goterris R, Hernandez-Boluda JC, Teruel A, Gomez C, Lis MJ, Terol MJ et al. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. Bone Marrow Transplant 2005; 36: 847-853. (Pubitemid 41655609)
10. Boeve S, Strupeck J, Creech S, Stiff PJ. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997-1003. (Pubitemid 38744785)
11. MacFarland R, Hard ML, Scarborough R, Badel K, Calandra G. A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. Biol Blood Marrow Transplant 2010; 16: 95-101.
12. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E et al. Pharmacokinetics and safety of AMD1300, a novel antagonist of the CXCR4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667-1673. (Pubitemid 30340812)
13. D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients who are poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356-363.
14. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimes. Blood 2009; 114: 1729-1735.
15. Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M et al. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 2010; 85: 1-5.
16. Physicians' Desk Reference. Red Book 2009: Pharmacy's Fundamental Reference, 113th Edition. Physicians' Desk Reference, New Jersey, 2009.
17. Delgado E, LeMaistre CF, Bachier C, Smith B, López-González G, Hougham M et al. Cost analysis of mobilization and autologous transplantation in patients who received AMD 3100 after failing standard mobilization. Blood (ASH Annual Meeting Abstracts) 2008; 112: 749a (Abstract 2151).